Dyne Therapeutics (DYN) Net Cash Flow (2019 - 2026)

Dyne Therapeutics (DYN) has reported Net Cash Flow for 8 consecutive years, with -$77.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Net Cash Flow fell 699.23% year-over-year to -$77.0 million; the TTM figure through Jun 2026 stood at $191.5 million (up 255.57% YoY), while the FY2025 annual figure was $458.3 million, up 46.23% from the prior year.
• Net Cash Flow advanced to -$77.0 million in Q2 2026 per DYN's latest filing, from -$140.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $336.2 million in Q2 2024 and bottomed at -$140.2 million in Q1 2026.
• Historically, Net Cash Flow has averaged $26.4 million across 5 years, with a median of $130000.0 in 2022.
• On a YoY basis, Net Cash Flow climbed as much as 2589.4% in 2024 and fell as far as 1016.35% in 2024.
• Dyne Therapeutics' Net Cash Flow stood at $27.2 million in 2022, then sank by 131.79% to -$8.7 million in 2023, then plunged by 1016.35% to -$96.7 million in 2024, then jumped by 431.01% to $320.1 million in 2025, then sank by 124.04% to -$77.0 million in 2026.
• Business Quant data shows DYN's Net Cash Flow at -$77.0 million in Q2 2026, -$140.2 million in Q1 2026, and $320.1 million in Q4 2025.